Caris Life Sciences (CAI) Receivables - Net (2024 - 2026)

Caris Life Sciences' Receivables - Net history runs 3 years deep, the most recent figure standing at $90.5 million for Q1 2026.

• On a quarterly basis, Receivables - Net changed N/A year-over-year to $90.5 million in Q1 2026; TTM through Mar 2026 was $90.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $112.1 million, up 27.08% from the prior year.
• Receivables - Net slipped to $90.5 million in Q1 2026 per CAI's latest filing, from $112.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $112.1 million in Q4 2025 and bottomed at $26.7 million in Q3 2025.
• The 3-year median for Receivables - Net is $88.2 million (2024), against an average of $73.7 million.
• Biggest YoY gain for Receivables - Net was 27.08% in 2025; the steepest drop was 27.08% in 2025.
• Year by year, Receivables - Net stood at $88.2 million in 2024, then increased by 27.08% to $112.1 million in 2025, then dropped by 19.28% to $90.5 million in 2026.
• Per Business Quant, the three latest CAI Receivables - Net figures stand at $90.5 million (Q1 2026), $112.1 million (Q4 2025), and $26.7 million (Q3 2025).